Acalabrutinib (Calquence): A Comprehensive Monograph on a Second-Generation BTK Inhibitor in Hematologic Malignancies

1.0 Introduction and Overview

Acalabrutinib represents a significant advancement in the targeted therapy of B-cell malignancies, embodying the principles of rational drug design to enhance the therapeutic window of its class. Marketed by AstraZeneca under the brand name Calquence, acalabrutinib is a second-generation, highly selective, and potent irreversible inhibitor of Bruton's tyrosine kinase (BTK).[1] BTK is an indispensable enzyme within the B-cell receptor (BCR) signaling pathway, a cascade that is fundamental to the proliferation, trafficking, and survival of both normal and malignant B-lymphocytes.[4] The clinical validation of BTK as a therapeutic target was firmly established by the first-in-class inhibitor, ibrutinib. However, the clinical utility of ibrutinib, while transformative, was frequently constrained by off-target toxicities stemming from its inhibition of other structurally related kinases, such as those in the TEC and EGFR families.[2] These off-target effects are associated with notable adverse events, including bleeding, atrial fibrillation, severe diarrhea, and skin rash, which can lead to dose reductions or treatment discontinuation.[2]

In this context, acalabrutinib (also known as ACP-196) was deliberately engineered to overcome these limitations. Its molecular structure was optimized for high potency and specificity for BTK, with the explicit goal of minimizing interaction with other kinases to theoretically reduce off-target adverse effects and improve overall tolerability.[1] This design philosophy—improving safety without compromising efficacy—is the central tenet of acalabrutinib's clinical development and its primary differentiator in the therapeutic landscape.

The profound potential of this strategy was validated not only through extensive clinical trials but also by a major strategic move in the pharmaceutical industry. In December 2015, while acalabrutinib was still in late-stage development, AstraZeneca acquired a 55% majority stake in its developer, Acerta Pharma, for an upfront payment of $4 billion, with a total potential deal value of $7 billion.[8] This landmark investment was a clear signal of confidence in acalabrutinib's potential to become a "best-in-class" agent and served as the cornerstone for AstraZeneca's new hematology franchise.[11] This report provides a comprehensive analysis of acalabrutinib, detailing its chemical properties, pharmacological profile, pivotal clinical trial data, comparative positioning, and regulatory status in the management of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

2.0 Chemical Profile and Pharmaceutical Formulation

The precise chemical identity and formulation of a therapeutic agent are foundational to its pharmacological behavior and clinical utility. Acalabrutinib is a well-characterized small molecule with specific identifiers and physicochemical properties. Furthermore, its formulation has evolved post-approval to address a key clinical challenge, thereby enhancing its applicability in a broader patient population.

2.1 Nomenclature and Identifiers

Acalabrutinib is identified by a standardized set of chemical names and database codes that ensure its unambiguous recognition in scientific literature, regulatory filings, and clinical practice. These key identifiers are consolidated in Table 1.

Table 1: Physicochemical and Identification Properties of Acalabrutinib

Property	Value	Source(s)
Generic Name	Acalabrutinib	1
Brand Name	Calquence	2
IUPAC Name	4-imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide	1
CAS Number	1420477-60-6	2
DrugBank ID	DB11703	1
PubChem CID	71226662	2
Molecular Formula	C26​H23​N7​O2​	1
Molecular Weight	465.517 g/mol	2
InChIKey	WDENQIQQYWYTPO-IBGZPJMESA-N	1
SMILES	CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5	1

The drug is also widely known by its developmental code name, ACP-196.[1]

2.2 Physicochemical Properties and Formulation Evolution

Acalabrutinib is a crystalline solid with established solubility in organic solvents such as dimethyl sulfoxide (DMSO) and dimethylformamide (DMF), and limited solubility in ethanol.[13] It was initially developed and approved for oral administration as a 100 mg hard capsule.[1]

A critical development in the lifecycle of acalabrutinib was the introduction of a new 100 mg film-coated tablet formulation, which received FDA approval in August 2022 and subsequent approval in the European Union.[1] This was not a simple manufacturing update but a strategic clinical enhancement designed to solve a significant pharmacological problem. The absorption of the original capsule formulation is pH-dependent, leading to a clinically significant drug-drug interaction with gastric acid-reducing agents. The prescribing information for the capsule form explicitly warns against co-administration with proton pump inhibitors (PPIs) and requires specific dosing intervals with H2-receptor antagonists and antacids, as these agents can decrease acalabrutinib exposure and potentially compromise its efficacy.[17] Given that many older cancer patients rely on these medications for conditions such as gastroesophageal reflux disease, this interaction posed a substantial barrier to treatment. The new tablet formulation was developed to overcome this limitation. Based on the ELEVATE-PLUS trials, the tablet was shown to be bioequivalent to the capsule but, crucially, its pharmacokinetics are not affected by changes in gastric pH.[1] This allows for the co-administration of Calquence tablets with PPIs, simplifying medication regimens, reducing the risk of suboptimal drug exposure, and expanding the eligible patient population that can benefit from this therapy.[1]

3.0 Clinical Pharmacology

The clinical efficacy and safety profile of acalabrutinib are direct consequences of its molecular mechanism, target selectivity, and pharmacokinetic properties. A comprehensive understanding of these pharmacological characteristics is essential to appreciate its role in the treatment of B-cell malignancies.

3.1 Mechanism of Action: Covalent Inhibition of Bruton's Tyrosine Kinase

Acalabrutinib is a targeted kinase inhibitor that exerts its antineoplastic effects by modulating the B-cell receptor (BCR) signaling pathway.[16] The central molecular target of acalabrutinib is Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase belonging to the Tec family.[5] BTK is a critical signaling node downstream of the BCR. Upon BCR activation, BTK becomes phosphorylated and, in turn, activates downstream pathways, including those involving phospholipase C gamma 2 (PLCγ2), which are essential for B-cell proliferation, differentiation, chemotaxis, and adhesion.[2] In many B-cell malignancies, this pathway is constitutively active, driving uncontrolled cell growth and survival.

Acalabrutinib functions as a small molecule inhibitor that irreversibly neutralizes the enzymatic activity of BTK. Both the parent drug and its primary active metabolite, ACP-5862, contain a reactive butynamide group that forms a permanent covalent bond with the thiol group of a specific cysteine residue (Cys481) located within the ATP-binding pocket of the BTK active site.[1] This irreversible binding locks the enzyme in an inactive state, effectively shutting down BTK-mediated signaling. The downstream consequence is the inhibition of B-cell activation and the suppression of survival pathways, which ultimately leads to apoptosis and a reduction in the proliferation of malignant B-cells that overexpress BTK.[1]

3.2 Target Selectivity and Pharmacodynamic Profile

The defining feature of acalabrutinib as a second-generation BTK inhibitor is its high degree of selectivity. It was rationally designed to bind potently to BTK while minimizing interactions with other kinases that share a homologous cysteine residue, a characteristic that distinguishes it from the first-generation inhibitor, ibrutinib.[1]

In vitro kinase assays have demonstrated that acalabrutinib has a much greater half-maximal inhibitory concentration (IC50​) for, or virtually no activity against, a panel of other kinases, including interleukin-2-inducible T-cell kinase (ITK), epidermal growth factor receptor (EGFR), ERBB2, ERBB4, Janus kinase 3 (JAK3), and multiple members of the SRC family of kinases (e.g., LYN, FYN, HCK).[1] The off-target inhibition of these kinases by ibrutinib is believed to be responsible for many of its characteristic adverse effects. For example, inhibition of ITK may affect T-cell function, while inhibition of EGFR is associated with skin rash and diarrhea, and inhibition of TEC family kinases may contribute to bleeding risk.[2] By avoiding these off-target interactions, acalabrutinib was developed with the expectation of a more favorable safety profile, particularly a lower incidence of cardiovascular events, severe diarrhea, and bleeding complications.[2] This enhanced selectivity forms the mechanistic basis for its improved tolerability, which has been confirmed in head-to-head clinical trials.

3.3 Pharmacokinetics (Absorption, Distribution, Metabolism, and Excretion)

The pharmacokinetic profile of acalabrutinib describes its movement into, through, and out of the body, which collectively determines the drug's exposure and dosing schedule.

Absorption: Following oral administration, acalabrutinib is rapidly absorbed, reaching peak plasma concentrations (Tmax​) in a median of 0.75 hours.[1] The geometric mean absolute bioavailability of the drug is 25%, indicating that a significant portion of the oral dose is subject to first-pass metabolism or incomplete absorption.[6]

Distribution: Acalabrutinib has a mean steady-state volume of distribution of approximately 34 L, suggesting it distributes into tissues beyond the plasma volume.[1] It is highly bound to human plasma proteins (97.5%), primarily to albumin (93.7%) and, to a lesser extent, alpha-1-acid glycoprotein (41.1%).[6]

Metabolism: The drug is extensively metabolized, predominantly by cytochrome P450 3A (CYP3A) enzymes in the liver and gut wall.[1] This heavy reliance on the CYP3A pathway makes acalabrutinib susceptible to significant drug-drug interactions with strong inhibitors or inducers of these enzymes. The primary active metabolite is ACP-5862. This metabolite is pharmacologically significant, as its systemic exposure (Area Under the Curve, AUC) is approximately two to three times greater than that of the parent drug. While it contributes to the overall therapeutic effect, ACP-5862 is about 50% less potent than acalabrutinib in its ability to inhibit BTK.[1]

Excretion: Acalabrutinib and its metabolites are eliminated primarily via the feces. Following a single radiolabeled dose, 84% of the dose was recovered in the feces and 12% was recovered in the urine. A very small fraction (<1%) of the dose is excreted as unchanged acalabrutinib, underscoring the extensive nature of its metabolism.[1]

Half-Life: A notable characteristic of acalabrutinib's pharmacokinetic profile is the very short terminal elimination half-life of the parent compound, which is approximately 0.9 hours (range: 0.6 to 2.8 hours).[1] This rapid clearance might initially suggest a need for more frequent dosing to maintain therapeutic concentrations. However, this is offset by two crucial pharmacodynamic and pharmacokinetic factors. First, the irreversible covalent binding to BTK means that the biological effect of the drug persists long after it has been cleared from the plasma; the inhibited BTK enzyme must be newly synthesized by the cell to restore function. Second, the major active metabolite, ACP-5862, has a substantially longer half-life of 6.9 hours, providing a sustained background of BTK inhibition.[1] This combination of irreversible binding and a long-acting active metabolite ensures continuous target engagement throughout the twice-daily dosing interval, providing a durable therapeutic effect.

4.0 Clinical Efficacy in Approved Indications

The regulatory approvals for acalabrutinib are supported by a robust clinical development program demonstrating significant efficacy in both mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The pivotal trials in these indications have established acalabrutinib as a standard of care in multiple treatment settings.

4.1 Mantle Cell Lymphoma (MCL)

Acalabrutinib has demonstrated durable efficacy in patients with MCL, a typically aggressive form of non-Hodgkin lymphoma, leading to approvals in both the relapsed/refractory and first-line settings.

4.1.1 Efficacy in Relapsed/Refractory (R/R) MCL: The ACE-LY-004 Trial (NCT02213926)

The initial approval of acalabrutinib was based on the results of the ACE-LY-004 trial, a Phase 2, multicenter, open-label, single-arm study involving 124 patients with R/R MCL who had received at least one prior therapy.[23] This study served as the basis for the FDA's accelerated approval in October 2017.[23]

The primary endpoint of the trial was the overall response rate (ORR). The investigator-assessed ORR was 81% (95% CI: 73-87), which included a high rate of deep responses, with 40% of patients achieving a complete response (CR) (95% CI: 31-49).[7] The responses proved to be durable with extended follow-up. At a median follow-up of 38.1 months, the median duration of response (DOR) was 28.6 months, and the median progression-free survival (PFS) was 22.0 months.[30] Importantly, the study also showed a substantial long-term survival benefit, with an estimated median overall survival (OS) of 59.2 months and an estimated 5-year OS rate of 49.5% in this heavily pre-treated population.[31]

4.1.2 Efficacy in First-Line Treatment of MCL: The ECHO Trial (NCT02972840)

The role of acalabrutinib in MCL was expanded to the first-line setting based on the pivotal Phase 3 ECHO trial. This was a randomized, double-blind, placebo-controlled study that enrolled 598 previously untreated MCL patients aged 65 or older who were not eligible for autologous stem cell transplantation.[32] Patients were randomized to receive standard chemoimmunotherapy consisting of bendamustine and rituximab (BR) plus either acalabrutinib or a placebo.

The trial successfully met its primary endpoint of improving PFS. With a median follow-up of 49.8 months, the addition of acalabrutinib to BR resulted in a median PFS of 66.4 months, compared to 49.6 months for placebo plus BR. This translated to a statistically significant 27% reduction in the risk of disease progression or death (Hazard Ratio 0.73; 95% CI: 0.57-0.94; p=0.016).[32] The combination also led to higher CR rates (66.6% vs 53.5%).[34] While the analysis of OS showed a positive trend favoring the acalabrutinib arm (HR 0.86), it did not reach statistical significance (p=0.27).[34] The interpretation of this OS data is complicated by the fact that the trial was conducted during the COVID-19 pandemic. A higher rate of COVID-19-related deaths was observed in the acalabrutinib arm (9.4%) compared to the placebo arm (6.7%).[34] This external factor likely acted as a significant confounder, potentially masking the true survival benefit of the more effective therapy. A prespecified sensitivity analysis that censored for these deaths revealed a more pronounced PFS benefit and a stronger, though still not statistically significant, trend toward improved OS (HR 0.75; p=0.0797).[36]

The robust PFS data from the ECHO trial led the FDA to grant traditional approval for acalabrutinib in combination with BR for first-line MCL in January 2025. This approval also converted the prior accelerated approval for R/R MCL to a full approval, solidifying acalabrutinib's role across the MCL treatment continuum.[32]

4.2 Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL)

Acalabrutinib has demonstrated profound and sustained efficacy in CLL, the most common leukemia in adults, leading to its approval as a monotherapy and in combination regimens for both treatment-naïve and relapsed/refractory disease.

4.2.1 Efficacy in Treatment-Naïve (TN) CLL/SLL: The ELEVATE-TN Trial (NCT02475681)

The ELEVATE-TN trial was a landmark Phase 3 study that established the superiority of acalabrutinib-based therapy over standard chemoimmunotherapy in 535 patients with previously untreated CLL.[40] The study featured a three-arm design, comparing acalabrutinib plus the anti-CD20 antibody obinutuzumab (A+O), acalabrutinib monotherapy (A), and the chemoimmunotherapy regimen of obinutuzumab plus chlorambucil (Clb+O).

The trial met its primary endpoint, with both acalabrutinib arms demonstrating a profound PFS benefit. At a long-term median follow-up of 74.5 months, the median PFS was not reached in either the A+O or A arms, compared to just 27.8 months in the Clb+O arm. The hazard ratio for disease progression or death was 0.14 for the A+O combination and 0.24 for acalabrutinib monotherapy when compared to chemoimmunotherapy (both p<0.0001).[42] The estimated 6-year PFS rates starkly illustrate this benefit: 78% for A+O, 62% for A, and only 17% for Clb+O.[42]

This trial also provided a unique opportunity to assess the contribution of obinutuzumab. The combination of A+O was found to be statistically superior to acalabrutinib monotherapy, with an HR for PFS of 0.58 (p=0.0229), confirming that the addition of an anti-CD20 antibody can further deepen and prolong responses.[42] Furthermore, a significant OS benefit was observed for the A+O combination versus the chemoimmunotherapy arm (HR 0.62; p=0.0349).[42] The efficacy of acalabrutinib was maintained across all subgroups, including patients with high-risk genomic features such as del(17p) and/or

TP53 mutations.[42]

4.2.2 Efficacy in Relapsed/Refractory (R/R) CLL/SLL: The ASCEND Trial (NCT02970318)

For patients with R/R CLL, the Phase 3 ASCEND trial confirmed the superiority of acalabrutinib over standard-of-care regimens.[45] This study randomized 310 patients to receive either acalabrutinib monotherapy or the investigator's choice of two commonly used regimens: idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR).

The trial was stopped early at a planned interim analysis due to compelling evidence of efficacy.[47] The final analysis, with a median follow-up of approximately 4 years, confirmed a durable and significant PFS benefit for acalabrutinib. The median PFS was not reached for patients treated with acalabrutinib, compared to 16.8 months for those in the IdR/BR arm (p<0.001).[45] The 42-month PFS rates were 62% for the acalabrutinib arm versus only 19% for the comparator arm. While median OS was not reached in either arm, the 42-month OS rates numerically favored acalabrutinib (78% vs 65%).[45]

The collective data from these pivotal trials are summarized in Table 2, underscoring the consistent and robust efficacy of acalabrutinib across different B-cell malignancies and lines of therapy.

Table 2: Summary of Efficacy Outcomes from Pivotal Phase 3 Trials

Trial (Indication)	Patient Population	Arms	Primary Endpoint	Key Result (Median PFS; HR [95% CI]; p-value)	Key Secondary Outcome(s)	Source(s)
ECHO (1L MCL)	598 TN MCL pts, ≥65 yrs, ASCT-ineligible	Acalabrutinib + BR vs. Placebo + BR	PFS	66.4 vs. 49.6 months; HR 0.73 [0.57-0.94]; p=0.016	OS Trend (HR 0.86); Higher CR Rate (66.6% vs 53.5%)	32
ELEVATE-TN (TN CLL)	535 TN CLL pts	A+O vs. A vs. Clb+O	PFS (vs. Clb+O)	A+O: NR vs. 27.8 mo; HR 0.14 [0.10-0.19]; p<0.0001 A: NR vs. 27.8 mo; HR 0.24 [0.17-0.34]; p<0.0001	A+O showed OS benefit vs. Clb+O (HR 0.62); A+O superior PFS vs. A (HR 0.58)	42
ASCEND (R/R CLL)	310 R/R CLL pts	Acalabrutinib vs. IdR or BR	PFS	NR vs. 16.8 months; HR 0.27; p<0.001	42-month OS: 78% vs. 65%	45
Abbreviations: 1L = First-Line; A = Acalabrutinib; A+O = Acalabrutinib + Obinutuzumab; ASCT = Autologous Stem Cell Transplant; BR = Bendamustine + Rituximab; CI = Confidence Interval; Clb+O = Chlorambucil + Obinutuzumab; CLL = Chronic Lymphocytic Leukemia; CR = Complete Response; HR = Hazard Ratio; IdR = Idelalisib + Rituximab; MCL = Mantle Cell Lymphoma; NR = Not Reached; OS = Overall Survival; PFS = Progression-Free Survival; R/R = Relapsed/Refractory; TN = Treatment-Naïve.

5.0 Comparative Analysis and Therapeutic Positioning

The therapeutic value of acalabrutinib is best understood in the context of its competitors within the BTK inhibitor class. Direct head-to-head clinical trials and indirect comparisons provide crucial insights into its relative efficacy and, more importantly, its safety profile compared to both first- and other second-generation agents.

5.1 Direct Comparison with Ibrutinib: Key Findings from the ELEVATE-RR Trial (NCT02477696)

The ELEVATE-RR trial was a landmark Phase 3 study, as it was the first to directly compare two BTK inhibitors head-to-head. The trial enrolled 533 patients with previously treated, high-risk R/R CLL (defined by the presence of del(17p) or del(11q)) and randomized them to receive either acalabrutinib or ibrutinib.[48]

The trial was strategically designed with a primary endpoint of non-inferiority for PFS. At a median follow-up of 40.9 months, acalabrutinib successfully met this endpoint, demonstrating equivalent efficacy to ibrutinib. The median PFS was identical in both arms at 38.4 months (HR 1.00; 95% CI: 0.79-1.27), confirming that patients do not sacrifice cancer control by choosing the second-generation agent.[48]

The critical findings of the trial emerged from the safety analyses. Acalabrutinib demonstrated a statistically significant and clinically meaningful superiority in its cardiovascular safety profile. The incidence of any-grade atrial fibrillation or flutter, a key secondary endpoint, was significantly lower in the acalabrutinib arm compared to the ibrutinib arm (9.4% vs. 16.0%, respectively; p=0.02).[49] This safety advantage extended to other important adverse events, as detailed in Table 3. Patients treated with acalabrutinib experienced significantly less hypertension, arthralgia, and diarrhea. Conversely, acalabrutinib was associated with a higher incidence of headache and cough, though these were typically low-grade and manageable.[49]

Crucially, the improved safety profile translated into better treatment tolerability. The rate of treatment discontinuation due to adverse events was notably lower for patients receiving acalabrutinib (16%) compared to those on ibrutinib (21.3%).[49] The ELEVATE-RR trial thus provides Level 1 evidence that acalabrutinib offers a superior risk-benefit profile to ibrutinib in R/R CLL, achieving the same level of efficacy with a significantly lower burden of cardiovascular and other toxicities. This has established acalabrutinib as a preferred BTK inhibitor, particularly for patients with pre-existing cardiac risk factors.

Table 3: Head-to-Head Comparison of Acalabrutinib and Ibrutinib in R/R CLL (ELEVATE-RR Trial)

Endpoint / Adverse Event	Acalabrutinib (n=268)	Ibrutinib (n=265)	Hazard Ratio / p-value	Source(s)
Median PFS (months)	38.4	38.4	HR 1.00 [95% CI: 0.79-1.27]	49
Any-Grade Atrial Fibrillation/Flutter	9.4%	16.0%	p=0.02	49
Any-Grade Hypertension	9.4%	23.2%	Statistically Significant	49
Any-Grade Bleeding Events	38.4%	51.3%	Statistically Significant	51
Any-Grade Diarrhea	34.6%	46.0%	Statistically Significant	49
Any-Grade Headache	34.6%	20.2%	Statistically Significant	49
Discontinuation due to AEs	16.0%	21.3%	Lower with Acalabrutinib	49

5.2 Indirect Comparisons with Zanubrutinib

In contrast to the definitive head-to-head data against ibrutinib, the relative positioning of acalabrutinib and the other prominent second-generation BTK inhibitor, zanubrutinib, is less clear. In the absence of a direct comparative trial, evidence is drawn from Matching-Adjusted Indirect Comparisons (MAICs) and real-world studies, both of which have inherent methodological limitations.

The available data from these indirect comparisons are notably contradictory. One MAIC that weighted patient data from the ASCEND (acalabrutinib) and ALPINE (zanubrutinib) trials concluded that the two drugs had similar PFS in R/R CLL. However, this same analysis suggested a more favorable safety profile for acalabrutinib, with a lower risk of serious adverse events, grade ≥3 hemorrhage, hypertension, and dose reductions due to toxicity.[53] Conversely, another MAIC using data from the same two trials concluded that zanubrutinib was associated with a significant advantage in both PFS and CR rate over acalabrutinib.[55] Further complicating the picture, a real-world evidence study suggested that patients treated with zanubrutinib had a longer time to treatment discontinuation compared to those on acalabrutinib, implying better overall persistence in a clinical practice setting.[56]

This conflicting evidence underscores the challenges of comparing drugs across different trials, even with advanced statistical adjustments. Patient populations, trial conduct, and endpoint definitions can vary in subtle but significant ways. Consequently, there is currently no definitive evidence to establish the superiority of either acalabrutinib or zanubrutinib over the other. The choice between these two highly effective and well-tolerated agents in clinical practice is often guided by physician familiarity, nuances in their side effect profiles, and patient-specific factors, highlighting a significant evidence gap that can only be resolved by a future head-to-head randomized trial.

5.3 The Clinical Significance of Enhanced BTK Selectivity

The development of second-generation BTK inhibitors was predicated on the hypothesis that greater selectivity for the BTK enzyme would translate into a better safety profile. The clinical data, particularly from the ELEVATE-RR trial, have validated this hypothesis. The reduced off-target inhibition of kinases such as TEC, EGFR, and ITK by acalabrutinib is the direct molecular reason for the observed lower rates of atrial fibrillation, hypertension, bleeding, and other adverse events compared to ibrutinib.[4] This demonstrates a successful application of rational drug design, where an improved understanding of the structure-activity relationship of a drug class led to the creation of a molecule with an improved therapeutic index.

6.0 Comprehensive Safety and Tolerability Profile

A thorough understanding of a drug's safety profile is paramount for its appropriate clinical use. Acalabrutinib is generally well-tolerated, but it is associated with a distinct set of adverse reactions and requires careful management of specific risks and drug interactions.

6.1 Analysis of Common and Serious Adverse Reactions

The safety profile of acalabrutinib has been characterized in a large population of patients across multiple clinical trials. The most frequently observed adverse events are typically manageable and of low grade.

Table 4: Summary of Common Adverse Reactions with Acalabrutinib Monotherapy

Adverse Reaction	Any Grade (%)	Grade ≥3 (%)	Source(s)
Hematologic
Neutropenia	36%	15%	27
Anemia	46%	11%	27
Thrombocytopenia	44%	12%	27
Non-Hematologic
Headache	39%	1.6%	27
Diarrhea	31-37%	3.2%	27
Infection (overall)	65-69%	14-22%	59
Fatigue	28-30%	0.8%	30
Myalgia (Muscle Pain)	21-22%	0.8%	30
Bruising	21%	0%	27
Cough	23-29%	Low	30
Nausea	22%	0.8%	30
Data primarily from pooled analyses and the ACE-LY-004 and ELEVATE-TN trials.

A unique aspect of acalabrutinib's profile is the high incidence of headache, reported in up to 39% of patients.[27] However, these events are overwhelmingly Grade 1 or 2 in severity, often transient, and rarely lead to treatment discontinuation. This contrasts with the more clinically significant adverse events associated with ibrutinib, establishing a different, and generally more manageable, tolerability profile.

6.2 Events of Clinical Interest: Management and Mitigation

Like all BTK inhibitors, acalabrutinib carries warnings for several events of clinical interest that require careful monitoring and management.

• Hemorrhage: Major hemorrhagic events, including fatal CNS and gastrointestinal bleeding, have occurred in approximately 3-4% of patients treated with acalabrutinib. Any-grade bleeding events, such as bruising and petechiae, are much more common. The risk of hemorrhage is increased in patients receiving concurrent antithrombotic agents (antiplatelets or anticoagulants).[3] Patients should be monitored for signs of bleeding, and consideration should be given to withholding acalabrutinib for 3 to 7 days before and after surgical procedures.[58]
• Infections: Serious and sometimes fatal bacterial, viral, and fungal infections have been reported. These include opportunistic infections such as reactivation of hepatitis B virus (HBV), Pneumocystis jirovecii pneumonia, and progressive multifocal leukoencephalopathy (PML).[3] Prophylactic measures should be considered for patients at high risk, and all patients should be monitored closely for signs and symptoms of infection.[58]
• Cytopenias: Treatment-emergent Grade 3 or 4 cytopenias are common, including neutropenia, anemia, and thrombocytopenia. Regular monitoring of complete blood counts is essential throughout treatment, and dose modifications may be required for severe or prolonged cytopenias.[3]
• Second Primary Malignancies: An increased incidence of second primary malignancies has been observed in patients treated with acalabrutinib, occurring in 12-18% of patients in clinical trials. The most common of these are skin cancers (basal cell carcinoma, squamous cell carcinoma), but other solid tumors have also been reported.[3] Patients should be advised to use sun protection and undergo regular skin cancer screenings.
• Cardiac Arrhythmias: Atrial fibrillation and atrial flutter have been reported, with Grade 3 or higher events occurring in approximately 1-3% of patients. The risk may be higher in patients with pre-existing cardiac risk factors, hypertension, or a history of arrhythmias. Patients should be monitored for symptoms such as palpitations, dizziness, or dyspnea.[3]

6.3 Clinically Significant Drug Interactions

Acalabrutinib's metabolism via the CYP3A pathway makes it highly susceptible to drug-drug interactions.

• CYP3A Inhibitors and Inducers:
• Strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir) can dramatically increase acalabrutinib plasma concentrations, raising the risk of toxicity. Concomitant use should be avoided. If a strong inhibitor must be used for a short duration (e.g., an antifungal for up to seven days), acalabrutinib treatment should be temporarily interrupted.[17]
• Moderate CYP3A inhibitors (e.g., fluconazole, diltiazem, erythromycin) can also increase acalabrutinib levels. When co-administered, the acalabrutinib dose should be reduced to 100 mg once daily.[20]
• Strong CYP3A inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort) can significantly decrease acalabrutinib plasma concentrations, which may lead to a loss of efficacy. Concomitant use should be avoided. If unavoidable, the dose of acalabrutinib should be increased to 200 mg twice daily.[20]
• Gastric Acid-Reducing Agents: This interaction is formulation-dependent.
• For the capsule formulation, which has pH-dependent solubility, co-administration with PPIs should be avoided. H2-receptor antagonists should be taken at least 10 hours after or 2 hours before the acalabrutinib capsule, and antacids should be separated by at least 2 hours.[17]
• The tablet formulation was specifically designed to overcome this issue and can be co-administered with PPIs, H2-receptor antagonists, and antacids without dose adjustment.[1]
• Food Interactions: Patients should be advised to avoid consuming grapefruit, grapefruit juice, and Seville oranges (often found in marmalade), as these are potent CYP3A inhibitors that can significantly increase acalabrutinib exposure and the risk of side effects.[20]

7.0 Regulatory and Prescribing Information

The clinical development of acalabrutinib has led to broad regulatory approvals in major markets worldwide. This section details its regulatory journey and summarizes key prescribing information.

7.1 Global Regulatory History

Acalabrutinib's path to approval was expedited by several special regulatory designations in recognition of its potential to address unmet needs in serious conditions.

• United States (FDA): Acalabrutinib received Breakthrough Therapy and Orphan Drug designations from the FDA.[2] Its approval timeline is as follows:
• October 31, 2017: Initial accelerated approval was granted for the treatment of adult patients with MCL who have received at least one prior therapy.[1]
• November 21, 2019: The indication was expanded to include the treatment of adult patients with CLL or SLL.[5]
• August 5, 2022: A new tablet formulation was approved for all existing indications, resolving the interaction with gastric acid-reducing agents.[1]
• January 16, 2025: Based on the confirmatory ECHO trial, the FDA granted traditional (full) approval for acalabrutinib in combination with BR for previously untreated MCL. This action also converted the accelerated approval for R/R MCL to a full approval.[2]
• European Union (EMA): Acalabrutinib was granted Orphan Medicinal Product designation by the EMA.[2]
• November 5, 2020: The initial marketing authorization was granted for the treatment of treatment-naïve CLL (as monotherapy or in combination with obinutuzumab) and for relapsed/refractory CLL (as monotherapy).[1]
• 2025: Following positive opinions from the Committee for Medicinal Products for Human Use (CHMP), the approval has been expanded to include fixed-duration combination regimens with venetoclax for TN CLL and for the first-line treatment of MCL in combination with BR.[73]

7.2 Dosage, Administration, and Management

The prescribing information provides clear guidance on dosing, administration, and management of toxicities and special populations.

Table 5: Recommended Dosage Modifications for Adverse Reactions and Drug Interactions

Condition	Recommendation	Source(s)
Adverse Reactions
Grade ≥3 Non-hematologic/Hematologic (1st/2nd occurrence)	Interrupt CALQUENCE. Resume at 100 mg twice daily once toxicity resolves to Grade ≤1 or baseline.	20
Grade ≥3 Non-hematologic/Hematologic (3rd occurrence)	Interrupt CALQUENCE. Resume at a reduced dose of 100 mg once daily once toxicity resolves.	20
Grade ≥3 Non-hematologic/Hematologic (4th occurrence)	Permanently discontinue CALQUENCE.	20
Drug Interactions
Strong CYP3A Inhibitor	Avoid co-administration. If short-term use is unavoidable, interrupt CALQUENCE.	20
Moderate CYP3A Inhibitor	Reduce CALQUENCE dose to 100 mg once daily.	20
Strong CYP3A Inducer	Avoid co-administration. If unavoidable, increase CALQUENCE dose to 200 mg twice daily.	20
PPIs (Capsule vs. Tablet)	Capsule: Avoid co-administration. Tablet: No dose adjustment needed.	1
H2-Antagonists (Capsule)	Take CALQUENCE 2 hours before taking the H2-antagonist.	17

• Standard Dosage and Administration: The recommended dose is 100 mg taken orally twice daily, approximately 12 hours apart. It can be taken with or without food. The tablets or capsules must be swallowed whole with water and should not be crushed, chewed, or opened.[17]
• Missed Dose: If a dose is missed by more than 3 hours, the patient should skip that dose and take the next one at its regularly scheduled time.[20]
• Special Populations:
• Hepatic Impairment: No dose adjustment is needed for patients with mild or moderate (Child-Pugh A or B) hepatic impairment. Use in patients with severe (Child-Pugh C) hepatic impairment is not recommended.[20]
• Renal Impairment: No dose adjustment is required for patients with mild or moderate renal impairment. The drug has not been studied in patients with severe renal impairment or those on dialysis.[17]
• Pregnancy and Lactation: Acalabrutinib may cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for at least one week after the final dose. Breastfeeding is not recommended during treatment and for two weeks after the last dose.[20]

7.3 Manufacturer and Commercial Details

Acalabrutinib was originally developed by Acerta Pharma. Following the 2015 acquisition, Acerta Pharma now operates as AstraZeneca's hematology research and development center of excellence. The drug is manufactured and marketed globally by AstraZeneca.[3]

8.0 Investigational Uses and Future Perspectives

While firmly established in MCL and CLL, the therapeutic potential of acalabrutinib is being explored in other contexts, reflecting its potent mechanism of action. This research provides a glimpse into the future directions of the drug's lifecycle.

8.1 Ongoing Research in Other Malignancies and Disease States

The biological rationale for BTK inhibition extends to other B-cell malignancies. Acalabrutinib has been or is currently being investigated in clinical trials for a wide range of hematologic cancers, including Waldenström macroglobulinemia, follicular lymphoma, diffuse large B-cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia.[1] The most promising avenues of research involve combination therapies. Numerous ongoing trials are evaluating acalabrutinib in combination with other novel agents, such as the BCL-2 inhibitor venetoclax and checkpoint inhibitors like durvalumab, with the goal of achieving deeper, more durable responses and potentially offering chemotherapy-free, fixed-duration treatment regimens.[83]

8.2 The Rationale and Outcomes of Acalabrutinib in COVID-19

The COVID-19 pandemic prompted an urgent search for existing drugs that could be repurposed to treat the disease. Acalabrutinib emerged as a candidate due to its immunomodulatory properties. The severe respiratory distress seen in COVID-19 patients was linked to a hyperinflammatory state, or "cytokine storm," driven by immune cells like macrophages.[88] Since BTK is known to play a role in macrophage activation and cytokine production, it was hypothesized that inhibiting BTK with acalabrutinib could mitigate this hyperinflammation.

This hypothesis was initially supported by a small, prospective, off-label clinical study involving 19 hospitalized patients with severe COVID-19. The results were encouraging, showing that most patients experienced a rapid reduction in inflammatory markers and an improvement in oxygenation after starting acalabrutinib.[88] This promising early data led to the initiation of larger, randomized, controlled clinical trials, known as the CALAVI trials, to rigorously test this hypothesis.[71]

However, the results from these more robust trials were disappointing. AstraZeneca announced in November 2020 that the CALAVI Phase 2 trials failed to meet their primary endpoint. Acalabrutinib did not significantly increase the proportion of patients who remained alive and free of respiratory failure compared to placebo.[5] The story of acalabrutinib in COVID-19 serves as a compelling case study in the scientific process. It illustrates how a sound biological rationale and promising observational data do not always translate into clinical benefit when subjected to the rigors of a randomized controlled trial. It highlights the importance of such trials in definitively establishing the efficacy of a therapeutic intervention.

9.0 Synthesis and Concluding Remarks

Acalabrutinib has successfully established itself as a cornerstone therapy in the management of B-cell malignancies, specifically mantle cell lymphoma and chronic lymphocytic leukemia. Its development as a second-generation BTK inhibitor was a deliberate and successful exercise in rational drug design, aimed at preserving the potent efficacy of its class while mitigating the off-target toxicities that limited the utility of the first-generation agent, ibrutinib.

The comprehensive clinical trial program has provided robust, long-term evidence of its efficacy. In both treatment-naïve and relapsed/refractory settings, acalabrutinib, either as a monotherapy or in combination with anti-CD20 antibodies, has demonstrated a profound and durable ability to control disease, significantly extending progression-free survival compared to traditional chemoimmunotherapy and other targeted agents.

The most defining feature of acalabrutinib is its favorable risk-benefit profile, which was definitively established in the head-to-head ELEVATE-RR trial. This study proved that acalabrutinib offers non-inferior efficacy to ibrutinib while conferring a significantly lower risk of clinically important cardiovascular adverse events, such as atrial fibrillation and hypertension. This finding has positioned acalabrutinib as a preferred BTK inhibitor for many clinicians, particularly in patients with cardiac comorbidities or those at risk for such events. The subsequent development of a tablet formulation that eliminates the drug interaction with common acid-reducing agents has further enhanced its clinical utility and ease of use.

While its precise positioning relative to the other second-generation BTK inhibitor, zanubrutinib, remains an area of ongoing debate due to the lack of direct comparative trials, acalabrutinib's extensive body of evidence supports its role as a standard of care. It offers a highly effective, well-tolerated, and durable treatment option that has fundamentally improved the therapeutic landscape for thousands of patients living with B-cell cancers worldwide.

Works cited

1. Acalabrutinib | C26H23N7O2 | CID 71226662 - PubChem, accessed July 24, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Acalabrutinib
2. Acalabrutinib - Wikipedia, accessed July 24, 2025, https://en.wikipedia.org/wiki/Acalabrutinib
3. MCL and CLL/SLL Treatment | CALQUENCE® (acalabrutinib) 100, accessed July 24, 2025, https://www.calquencehcp.com/
4. Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies - PMC - PubMed Central, accessed July 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8162209/
5. acalabrutinib | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed July 24, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=8912
6. Acalabrutinib: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 24, 2025, https://go.drugbank.com/drugs/DB11703
7. Acalabrutinib Receives FDA Approval for Mantle Cell Lymphoma - NCI, accessed July 24, 2025, https://www.cancer.gov/news-events/cancer-currents-blog/2017/acalabrutinib-fda-mantle-cell-lymphoma
8. AstraZeneca-Snags-Stake-Acerta - C&EN - American Chemical Society, accessed July 24, 2025, https://cen.acs.org/articles/93/i49/AstraZeneca-Snags-Stake-Acerta.html
9. UPDATE: AstraZeneca buys 55% stake in Acerta for $4 billion | BioPharma Dive, accessed July 24, 2025, https://www.biopharmadive.com/news/update-astrazeneca-buys-55-stake-in-acerta-for-4-billion/410772/
10. Acerta Pharma Announces Strategic Transaction with AstraZeneca, accessed July 24, 2025, https://www.fiercepharma.com/marketing/acerta-pharma-announces-strategic-transaction-astrazeneca
11. AstraZeneca completes transaction for majority equity stake investment in Acerta Pharma, accessed July 24, 2025, https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-completes-transaction-for-majority-equity-stake-investment-in-acerta-pharma-01022016.html
12. AstraZeneca enhances long-term growth through Oncology investment in Acerta Pharma, accessed July 24, 2025, https://www.astrazeneca.com/media-centre/press-releases/2015/AstraZeneca-enhances-long-term-growth-through-Oncology-investment-in-Acerta-Pharma.html
13. Acalabrutinib | CAS 1420477-60-6 | Cayman Chemical | Biomol.com, accessed July 24, 2025, https://www.biomol.com/products/chemicals/biochemicals/acalabrutinib-cay19899-1
14. Acalabrutinib (ACP-196, CAS Number: 1420477-60-6) | Cayman Chemical, accessed July 24, 2025, https://www.caymanchem.com/product/19899/acalabrutinib
15. Acalabrutinib | ACP-196 | CAS#1420477-60-6 | BTK inhibitor - MedKoo Biosciences, accessed July 24, 2025, https://www.medkoo.com/products/6712
16. 210259Orig1s000 - accessdata.fda.gov, accessed July 24, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/210259Orig1s000MultidisciplineR.pdf
17. Calquence, INN-acalabrutinib - EMA, accessed July 24, 2025, https://www.ema.europa.eu/en/documents/product-information/calquence-epar-product-information_en.pdf
18. FDA Approves Acalabrutinib Tablet Formulation in CLL/SLL and Relapsed/Refractory MCL, accessed July 24, 2025, https://www.cancernetwork.com/view/fda-approves-acalabrutinib-tablet-formulation-in-cll-sll-and-relapsed-refractory-mcl
19. Calquence tablet formulation approved in the EU for patients with chronic lymphocytic leukaemia - AstraZeneca, accessed July 24, 2025, https://www.astrazeneca.com/media-centre/press-releases/2023/calquence-tablet-formulation-approved-in-the-eu-for-patients-with-chronic-lymphocytic-leukaemia.html
20. Reference ID: 5512932 - accessdata.fda.gov, accessed July 24, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210259s011lbl.pdf
21. Acalabrutinib Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed July 24, 2025, https://www.drugs.com/dosage/acalabrutinib.html
22. Calquence tablet formulation approved in the US across current indications - AstraZeneca, accessed July 24, 2025, https://www.astrazeneca.com/media-centre/press-releases/2022/calquence-tablet-formulation-approved-in-the-us-across-current-indications.html
23. US FDA approves AstraZeneca's Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma, accessed July 24, 2025, https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-approves-astrazenecas-calquence-acalabrutinib-for-adult-patients-with-previously-treated-mantle-cell-lymphoma-24102017.html
24. Acalabrutinib (ACP-196) | BTK Inhibitor - MedchemExpress.com, accessed July 24, 2025, https://www.medchemexpress.com/Acalabrutinib.html
25. FDA Approves CALQUENCE - American College of Clinical Pharmacology, accessed July 24, 2025, https://accp1.org/Members/ACCP1/5Publications_and_News/FDA_Approves_CALQUENCE.aspx
26. An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma | ClinicalTrials.gov, accessed July 24, 2025, https://clinicaltrials.gov/study/NCT02213926
27. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial - PubMed, accessed July 24, 2025, https://pubmed.ncbi.nlm.nih.gov/29241979/
28. FDA grants accelerated approval to acalabrutinib for mantle cell lymphoma, accessed July 24, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-acalabrutinib-mantle-cell-lymphoma
29. FDA Approves Acalabrutinib for Mantle Cell Lymphoma - CancerNetwork, accessed July 24, 2025, https://www.cancernetwork.com/view/fda-approves-acalabrutinib-mantle-cell-lymphoma
30. Calquence shows long-term efficacy and tolerability at three years for patients with relapsed or refractory mantle cell lymphoma - AstraZeneca, accessed July 24, 2025, https://www.astrazeneca.com/media-centre/press-releases/2020/calquence-shows-long-term-efficacy-and-tolerability-at-three-years-for-patients-with-relapsed-or-refractory-mantle-cell-lymphoma.html
31. Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed refractory mantle cell lymphoma, including those with poor prognostic factors, accessed July 24, 2025, https://pure.eur.nl/files/126124881/Final_results_and_overall_survival_data_from_a_phase_II_study_of_acalabrutinib_monotherapy_in_patients_with_relapsed_refractory_mantle_cell_lymphoma_including_those_with_poor_prognostic_factors.pdf
32. FDA approves acalabrutinib with bendamustine and rituximab for previously untreated mantle cell lymphoma, accessed July 24, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-acalabrutinib-bendamustine-and-rituximab-previously-untreated-mantle-cell-lymphoma
33. FDA Grants 2 Traditional Approvals for Acalabrutinib, accessed July 24, 2025, https://www.ajmc.com/view/fda-grants-2-traditional-approvals-for-acalabrutinib
34. Acalabrutinib Plus Chemoimmunotherapy Improves Progression-Free Survival in Older Patients With Mantle Cell Lymphoma - The ASCO Post, accessed July 24, 2025, https://ascopost.com/issues/august-25-2024/acalabrutinib-plus-chemoimmunotherapy-improves-progression-free-survival-in-older-patients-with-mantle-cell-lymphoma/
35. www.astrazeneca\-us.com, accessed July 24, 2025, https://www.astrazeneca-us.com/media/press-releases/2025/calquence-acalabrutinib-plus-chemoimmunotherapy-approved-in-the-us-for-patients-with-previously-untreated-mantle-cell-lymphoma.html#:~:text=Results%20from%20the%20ECHO%20trial,0.94%3B%20p%3D0.016)..&sa=D&source=editors&ust=1753361225087181&usg=AOvVaw3U1Do1tn7E6hUI9iZv_n2p)
36. Frontline Acalabrutinib/BR Regimen Improves PFS in MCL - Targeted Oncology, accessed July 24, 2025, https://www.targetedonc.com/view/frontline-acalabrutinib-br-regimen-improves-pfs-in-mcl
37. FDA Approves Acalabrutinib Combo in Previously Untreated MCL - CancerNetwork, accessed July 24, 2025, https://www.cancernetwork.com/view/fda-approves-acalabrutinib-plus-combo-in-previously-untreated-mcl
38. Calquence plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma - AstraZeneca, accessed July 24, 2025, https://www.astrazeneca.com/media-centre/press-releases/2025/calquence-combination-approved-in-us-for-1l-mcl.html
39. The U.S. Food and Drug Administration (FDA) Approves Acalabrutinib (Calquence) for Mantle Cell Lymphoma, accessed July 24, 2025, https://lymphoma.org/news/the-u-s-food-and-drug-administration-fda-approves-acalabrutinib-calquence-for-mantle-cell-lymphoma/
40. EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia - PMC - PubMed Central, accessed July 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7930415/
41. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Elevate-TN four-year follow up. - ASCO Publications, accessed July 24, 2025, https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.7509
42. Longer Follow-up Results of ELEVATE-TN trial of Acalabrutinib ± Obinutuzumab Versus Obinutuzumab + Chlorambucil in Patients with Treatment-Naive CLL - Conference Correspondent, accessed July 24, 2025, https://conference-correspondent.com/highlights/ash/ash-2023-cll/longer-follow-up-results-of-elevate-tn-trial-of-acalabrutinib-obinutuzumab-versus-obinutuzumab-chlorambucil-in-patients-with-treatment-naive-cll
43. How Effective Is CALQUENCE® (acalabrutinib)? | CLL, accessed July 24, 2025, https://www.calquence.com/why-calquence/how-effective-calquence-cll.html
44. Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials - PubMed Central, accessed July 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11255369/
45. Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results - PubMed, accessed July 24, 2025, https://pubmed.ncbi.nlm.nih.gov/36398134/
46. Final ASCEND Results Confirm Acalabrutinib as a Standard for Relapsed CLL, accessed July 24, 2025, https://ascopost.com/issues/august-25-2020/final-ascend-results-confirm-acalabrutinib-as-a-standard-for-relapsed-cll/
47. Calquence Phase III ASCEND trial met primary endpoint at interim analysis in relapsed or refractory chronic lymphocytic leukaemia and will stop early - AstraZeneca, accessed July 24, 2025, https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-phase-iii-ascend-trial-met-primary-endpoint-at-interim-analysis-in-relapsed-or-refractory-chronic-lymphocytic-leukaemia-and-will-stop-early-07052019.html
48. Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients with Chronic Lymphocytic Leukemia | Blood | American Society of Hematology, accessed July 24, 2025, https://ashpublications.org/blood/article/140/Supplement%201/4156/491831/Comparing-Acalabrutinib-and-Ibrutinib-in-the-Real
49. ELEVATE-RR Trial Acalabrutinib as Effective as Ibrutinib With Fewer Cardiac Effects in Resistant CLL - The ASCO Post, accessed July 24, 2025, https://ascopost.com/issues/september-10-2021/elevate-rr-trial-acalabrutinib-as-effective-as-ibrutinib-with-fewer-cardiac-effects-in-resistant-cll/
50. Acalabrutinib Meets Primary End Point Versus Ibrutinib in Previously Treated, High-Risk CLL - CancerNetwork, accessed July 24, 2025, https://www.cancernetwork.com/view/acalabrutinib-meets-primary-end-point-versus-ibrutinib-in-previously-treated-high-risk-cll
51. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial - PubMed, accessed July 24, 2025, https://pubmed.ncbi.nlm.nih.gov/37390310/
52. More Favorable Safety Profile of Acalabrutinib Vs Ibrutinib Validated for CLL, accessed July 24, 2025, https://www.cancernetwork.com/view/more-favorable-safety-profile-of-acalabrutinib-vs-ibrutinib-validated-for-cll
53. Efficacy and Safety of Acalabrutinib Versus Zanubrutinib - CLL Society, accessed July 24, 2025, https://cllsociety.org/2023/10/efficacy-and-safety-of-acalabrutinib-versus-zanubrutinib/
54. P642: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA - PMC, accessed July 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10429468/
55. Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC) - PubMed, accessed July 24, 2025, https://pubmed.ncbi.nlm.nih.gov/40656602/
56. Comparing real-world treatment patterns and outcomes of zanubrutinib and acalabrutinib in CLL/SLL at University of California academic health centers. - ASCO Publications, accessed July 24, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.e23263
57. BTK inhibitors in CLL: second-generation drugs and beyond | Blood Advances, accessed July 24, 2025, https://ashpublications.org/bloodadvances/article/8/9/2300/515303/BTK-inhibitors-in-CLL-second-generation-drugs-and
58. Reference ID: 4174611 This label may not be the latest approved by FDA. For current labeling information, please visit https:// - accessdata.fda.gov, accessed July 24, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf
59. CALQUENCE® (acalabrutinib) tablets, for oral use - accessdata.fda.gov, accessed July 24, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216387Orig2s000Correctedlbl.pdf
60. A Guide for Management of Patients With R/R MCL on CALQUENCE, accessed July 24, 2025, https://www.calquencehcp.com/content/dam/open-digital/hcp-cal/us/en/pdf/management-of-patients-with-mcl.pdf
61. Treatment for CLL/SLL and R/R MCL | CALQUENCE® (acalabrutinib), accessed July 24, 2025, https://www.calquence.com/
62. Calquence: Side effects, uses, cost, alternatives, and more - Medical News Today, accessed July 24, 2025, https://www.medicalnewstoday.com/articles/calquence
63. BTK Inhibitor for Adult Patients with CLL or SLL - Calquence, accessed July 24, 2025, https://www.calquencehcp.com/cll.html
64. Calquence (acalabrutinib) dosing, indications, interactions, adverse effects, and more, accessed July 24, 2025, https://reference.medscape.com/drug/calquence-acalabrutinib-1000209
65. Calquence interactions: Other medications, alcohol, and more, accessed July 24, 2025, https://www.medicalnewstoday.com/articles/drugs-calquence-interactions
66. acalabrutinib patient.pdf - Cancer Care Ontario, accessed July 24, 2025, https://www.cancercareontario.ca/en/system/files_force/acalabrutinib%20patient.pdf?download=1
67. Acalabrutinib (oral route) - Side effects & dosage - Mayo Clinic, accessed July 24, 2025, https://www.mayoclinic.org/drugs-supplements/acalabrutinib-oral-route/description/drg-20406641
68. Acalabrutinib (Calquence ®) | OncoLink, accessed July 24, 2025, https://www.oncolink.org/cancer-treatment/oncolink-rx/acalabrutinib-calquence-R
69. Calquence and Alcohol/Food Interactions - Drugs.com, accessed July 24, 2025, https://www.drugs.com/food-interactions/acalabrutinib,calquence.html
70. Calquence Food, Alcohol, Supplements and Drug Interactions - ScriptSave WellRx, accessed July 24, 2025, https://www.wellrx.com/calquence/lifestyle-interactions/
71. Calquence (acalabrutinib) FDA Approval History - Drugs.com, accessed July 24, 2025, https://www.drugs.com/history/calquence.html
72. Calquence | European Medicines Agency (EMA), accessed July 24, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/calquence
73. Fixed-duration Calquence-based regimens approved in EU for patients with chronic lymphocytic leukaemia in the 1st-line setting - AstraZeneca, accessed July 24, 2025, https://www.astrazeneca.com/media-centre/press-releases/2025/fixed-duration-calquence-approved-in-eu-for-1l-cll.html
74. EMA Recommends Extension of Therapeutic Indications for Acalabrutinib | ESMO, accessed July 24, 2025, https://www.esmo.org/oncology-news/ema-recommends-extension-of-therapeutic-indications-for-acalabrutinib
75. EMA approves acalabrutinib combination for patients with previously untreated MCL, accessed July 24, 2025, https://lymphomahub.com/medical-information/ema-approves-acalabrutinib-combination-for-patients-with-previously-untreated-mcl
76. AstraZeneca: EU Approves Calquence Combination For 1st-line Mantle Cell Lymphoma, accessed July 24, 2025, https://www.nasdaq.com/articles/astrazeneca-eu-approves-calquence-combination-1st-line-mantle-cell-lymphoma
77. Dosing | CALQUENCE® (acalabrutinib) 100 mg tablets | For HCPs, accessed July 24, 2025, https://www.calquencehcp.com/dosing.html
78. How Do I Take CALQUENCE® (acalabrutinib)? | CLL, accessed July 24, 2025, https://www.calquence.com/taking-calquence/how-take-calquence-cll.html
79. 3884-Acalabrutinib | eviQ, accessed July 24, 2025, https://www.eviq.org.au/haematology-and-bmt/leukaemias/chronic-lymphocytic-leukaemia/3884-acalabrutinib
80. CALQUENCE™ Cares Support Hub for CLL/SLL, accessed July 24, 2025, https://www.calquence.com/resources/cares-hub-cll.html
81. What We Do | Acerta Pharma - A Member of the AstraZeneca Group, accessed July 24, 2025, https://www.acerta-pharma.com/science.html
82. www.astrazeneca.com, accessed July 24, 2025, https://www.astrazeneca.com/media-centre/press-releases/2022/calquence-tablet-formulation-approved-in-the-us-across-current-indications.html#:~:text=AstraZeneca's%20new%20tablet%20formulation%20of,MCL)%2C%20which%20is%20approved%20under%252C%2520which%2520is%2520approved%2520under&sa=D&source=editors&ust=1753361225117078&usg=AOvVaw1PoXjdHAH3s4dMp9BI02nM)
83. Clinical Trials Using Acalabrutinib - NCI, accessed July 24, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/acalabrutinib?pn=1
84. Acalabrutinib Recruiting Phase 2 Trials for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Treatment - DrugBank, accessed July 24, 2025, https://go.drugbank.com/drugs/DB11703/clinical_trials?conditions=DBCOND0153542&phase=2&purpose=treatment&status=recruiting
85. Acalabrutinib Recruiting Phase 2 Trials for Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma Treatment | DrugBank Online, accessed July 24, 2025, https://go.drugbank.com/drugs/DB11703/clinical_trials?conditions=DBCOND0028332%2CDBCOND0023538&phase=2&purpose=treatment&status=recruiting
86. Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL | ClinicalTrials.gov, accessed July 24, 2025, https://www.clinicaltrials.gov/study/NCT03580928
87. A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL | ClinicalTrials.gov, accessed July 24, 2025, https://clinicaltrials.gov/study/NCT05197192
88. Study identifies potential approach to treat severe respiratory distress in patients with COVID-19 | National Institutes of Health (NIH), accessed July 24, 2025, https://www.nih.gov/news-events/news-releases/study-identifies-potential-approach-treat-severe-respiratory-distress-patients-covid-19